Literature DB >> 18179828

Factors determining antibody distribution in tumors.

Greg M Thurber1, Michael M Schmidt, K Dane Wittrup.   

Abstract

The development of antibody therapies for cancer is increasing rapidly, primarily owing to their specificity. Antibody distribution in tumors is often extremely uneven, however, leading to some malignant cells being exposed to saturating concentrations of antibody, whereas others are completely untargeted. This is detrimental because large regions of cells escape therapy, whereas other regions might be exposed to suboptimal concentrations that promote a selection of resistant mutants. The distribution of antibody depends on a variety of factors, including dose, affinity, antigens per cell and molecular size. Because these parameters are often known or easily estimated, a quick calculation based on simple modeling considerations can predict the uniformity of targeting within a tumor. Such analyses should enable experimental researchers to identify in a straightforward way the limitations in achieving evenly distributed antibody, and design and test improved antibody therapeutics more rationally.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18179828      PMCID: PMC2820301          DOI: 10.1016/j.tips.2007.11.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  28 in total

1.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Authors:  Christilyn P Graff; K Dane Wittrup
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

2.  Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

Authors:  U B Nielsen; G P Adams; L M Weiner; J D Marks
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

3.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.

Authors:  R K Jain; L T Baxter
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 4.  Lymphatic function, lymphangiogenesis, and cancer metastasis.

Authors:  M A Swartz; M Skobe
Journal:  Microsc Res Tech       Date:  2001-10-15       Impact factor: 2.769

Review 5.  Transport of molecules, particles, and cells in solid tumors.

Authors:  R K Jain
Journal:  Annu Rev Biomed Eng       Date:  1999       Impact factor: 9.590

Review 6.  Trafficking of the ErbB receptors and its influence on signaling.

Authors:  H Steven Wiley
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

7.  Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.

Authors:  Rosana B Michel; Rita Ochakovskaya; M Jules Mattes
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

Review 8.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

9.  Measurement of macromolecular diffusion coefficients in human tumors.

Authors:  Edward B Brown; Yves Boucher; Selim Nasser; Rakesh K Jain
Journal:  Microvasc Res       Date:  2004-05       Impact factor: 3.514

10.  Penetration and binding of antibodies in experimental human solid tumors grown in mice.

Authors:  G L Ong; M J Mattes
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

View more
  109 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Implicit and explicit prior information in near-infrared spectral imaging: accuracy, quantification and diagnostic value.

Authors:  Brian W Pogue; Scott C Davis; Frederic Leblond; Michael A Mastanduno; Hamid Dehghani; Keith D Paulsen
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

3.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

4.  Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Authors:  Valeria Arkadash; Gal Yosef; Jason Shirian; Itay Cohen; Yuval Horev; Moran Grossman; Irit Sagi; Evette S Radisky; Julia M Shifman; Niv Papo
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

5.  Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Biotechnol Bioeng       Date:  2011-07-19       Impact factor: 4.530

Review 6.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

7.  Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.

Authors:  Jun Wang; Darren K W Chan; Arindam Sen; Wen Wee Ma; Robert M Straubinger
Journal:  Mol Cancer Ther       Date:  2019-07-30       Impact factor: 6.261

8.  Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

10.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.

Authors:  Carol M Lee; Ian F Tannock
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.